204 related articles for article (PubMed ID: 36761480)
41. Identification and validation of N6-methyladenosine (m6A)-related lncRNAs signature for predicting the prognosis of laryngeal carcinoma, especially for smoking patients.
Chen Y; Chen C; Gao G; Zeng C; Chen Z; Lin G; Yao G; Nian S; Chen X; Weng S; Gu X; Lin C
Front Genet; 2023; 14():1292164. PubMed ID: 38028627
[TBL] [Abstract][Full Text] [Related]
42. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
43. N6-Methyladenosine Related Long Non-Coding RNAs and Immune Cell Infiltration in the Tumor Microenvironment of Gastric Cancer.
Yu ZL; Zhu ZM
Biol Proced Online; 2021 Aug; 23(1):15. PubMed ID: 34332535
[TBL] [Abstract][Full Text] [Related]
44. Identification and validation of lncRNAs involved in m6A regulation for patients with ovarian cancer.
Zheng J; Guo J; Cao B; Zhou Y; Tong J
Cancer Cell Int; 2021 Jul; 21(1):363. PubMed ID: 34238292
[TBL] [Abstract][Full Text] [Related]
45. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
46. N6-Methylandenosine-Related lncRNAs Predict Prognosis and Immunotherapy Response in Bladder Cancer.
Zhang Y; Zhu B; He M; Cai Y; Ying X; Jiang C; Ji W; Zeng J
Front Oncol; 2021; 11():710767. PubMed ID: 34458149
[TBL] [Abstract][Full Text] [Related]
47. Identification of N6-Methyladenosine-Related LncRNAs for Predicting Overall Survival and Clustering of a Potentially Novel Molecular Subtype of Breast Cancer.
Zhong X; Li J; Wu X; Wu X; Hu L; Ding B; Qian L
Front Oncol; 2021; 11():742944. PubMed ID: 34722294
[TBL] [Abstract][Full Text] [Related]
48. Identification of N6-methylandenosine related lncRNA signatures for predicting the prognosis and therapy response in colorectal cancer patients.
Li Z; Liu Y; Yi H; Cai T; Wei Y
Front Genet; 2022; 13():947747. PubMed ID: 36246627
[TBL] [Abstract][Full Text] [Related]
49. Prognostic N6-methyladenosine (m6A)-related lncRNA patterns to aid therapy in pancreatic ductal adenocarcinoma.
Wang Y; Ji Y; Xu Q; Huang W
Front Genet; 2022; 13():866340. PubMed ID: 36226185
[No Abstract] [Full Text] [Related]
50. The development and validation of a m6A-lncRNAs based prognostic model for overall survival in lung squamous cell carcinoma.
Huang H; Wu W; Lu Y; Pan X
J Thorac Dis; 2022 Oct; 14(10):4055-4072. PubMed ID: 36389308
[TBL] [Abstract][Full Text] [Related]
51. Expression and prognostic signatures of m6A-related lncRNAs in hepatocellular carcinoma.
Hao K; Li J; Zhang Y; Zhao W; Chen X; Xu J; Tian Y; Li X; Fen J; He X
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4429-4441. PubMed ID: 36121511
[TBL] [Abstract][Full Text] [Related]
52. m6A-related long noncoding RNAs predict prognosis and indicate therapeutic response in endometrial carcinoma.
Zhou X; Zhang H; Duan Y; Zhu J; Dai H
J Clin Lab Anal; 2023 Jan; 37(1):e24813. PubMed ID: 36525280
[TBL] [Abstract][Full Text] [Related]
53. N6-Methylandenosine-Related lncRNA Signature Is a Novel Biomarkers of Prognosis and Immune Response in Colon Adenocarcinoma Patients.
Zhang P; Liu G; Lu L
Front Cell Dev Biol; 2021; 9():703629. PubMed ID: 34336856
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive Analysis of N6-Methylandenosine-Related Long Non-Coding RNAs Signature in Prognosis and Tumor Microenvironment of Bladder Cancer.
Chen K; Zhu S; Yu W; Xia Y; Xing J; Geng J; Cheng F
Front Oncol; 2022; 12():774307. PubMed ID: 35141159
[TBL] [Abstract][Full Text] [Related]
55. m6A-Related lncRNA to Develop Prognostic Signature and Predict the Immune Landscape in Bladder Cancer.
Li Z; Li Y; Zhong W; Huang P
J Oncol; 2021; 2021():7488188. PubMed ID: 34349798
[TBL] [Abstract][Full Text] [Related]
56. A N6-methyladenosine-related long noncoding RNAs model for predicting prognosis in oral squamous cell carcinoma: Association with immune cell infiltration and tumor metastasis.
Yang Q; Cheng C; Zhu R; Guo F; Lai R; Liu X; Li M
Oral Oncol; 2022 Apr; 127():105771. PubMed ID: 35189585
[TBL] [Abstract][Full Text] [Related]
57. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
58. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
59. N6-Methyladenosine-Related Long Non-coding RNA Signature Associated With Prognosis and Immunotherapeutic Efficacy of Clear-Cell Renal Cell Carcinoma.
Ma T; Wang X; Wang J; Liu X; Lai S; Zhang W; Meng L; Tian Z; Zhang Y
Front Genet; 2021; 12():726369. PubMed ID: 34721523
[TBL] [Abstract][Full Text] [Related]
60. m6A-related lncRNAs predict prognosis and indicate cell cycle in gastric cancer.
Wan D; He L; Guo C; Zhong Z; Yan X; Cao J; Xu Q; Zhang H; Duan B
Front Genet; 2023; 14():1140218. PubMed ID: 37408779
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
